Introduction
Cardiovascular disease (CVD), a leading cause of morbidity and mortality in developed countries, has a significant genetic background. Although monogenic Mendelian diseases leading to CVD, such as familial hypercholesterolemia or Tangier disease (Bodzioch et al. 1999) , are generally well recognized and their genetic backgrounds have been explained, such diseases only account for a very low proportion of CVD and do not explain the high prevalence of CVD within the general population.
The vast majority of CVD is of a polygenic character, it means that the disease has a late onset, a mild genotype, and inheritance based on the presence of risky alleles of many common polymorphisms with relatively minor effects.
The first GWAS to focus on CVD risk factors were performed roughly ten years ago and have significantly moved forward our understanding of the genetic architecture of CVD. GWA technology (Dubé and Hegele 2013, Uitterlinden 2016) facilitates the analysis of an enormous number of single nucleotide polymorphisms Vol. 66 (SNPs) in one individual over a very short period of time.
SNPs are the most common genetic variants. It is estimated that there are about 10 million common SNPs (with a frequency of minor alleles at over 1 % in the population) within the human genome. They are supposed to have a major genetic influence on disease heritability and are known to be the best markers of different chromosomal loci due to their very high numbers across the genome.
In GWAS, SNPs are analyzed using microarray "SNP-chips". One chip is used to analyze DNA from one subject and the results can be used to calculate risk for arbitrary known and available anthropometric, biochemical or clinical characteristics. Indeed, they can be used to analyze any type of disease in which at least some part of the genetic background is expected to have an influence, simply by comparing genotype frequencies in patients and healthy subjects.
For the first chips, SNPs have been selected primarily according to their prevalence (at least 5 % for minor alleles) and in order to mark as many chromosomal loci as possible. The potential functional importance has not been an issue in this type of SNP selection. As individual neighbouring SNPs are often linked together (linkage disequilibrium), only one of these clustered (and simultaneously inherited) SNPs needs to be included on the chip in order to characterize the entire region.
As hundreds of thousands of SNPs are analyzed simultaneously, the statistical threshold used needs to be very stringent. Based on simple Bonferroni correction, the GWAS significance threshold is set at P<10 -8 .
P values are calculated for each SNP individually and the results are then summarized into one single figure, which is called a Manhattan plot. Despite the overwhelming efforts made, GWAS also present some pitfalls (Table 1) . Frequently, the most important functional SNPs are not included on the chip. In fact, detailed analysis of the identified loci often leads to the detection of variants with much higher effects than originally described (Sanna et al. 2011) . Another weak point pertains to SNP frequency, since some rare variants with strong effects are also omitted simply because they have not been included on the chip. The last issue not to be overlooked is the necessity for high quality controls. Not all SNPs included on chips pass through quality controls, which can also potentially lead to some important variants being neglected.
As mentioned above, dyslipidemia (elevated plasma lipids) is associated with increased risk of atherosclerosis development and cardiovascular disease. However, its role in total mortality determination is controversial (Anderson et al. 1987 , Arsenault et al. 2011 , Hubáček 2015 , Liu et al. 2013 , Pikhart et al. 2015 , Piťha et al. 2016 , van Wijk et al. 2009 ). Lipids (mainly cholesterol and triglycerides) are transported through the body in heterogeneous complexes along with proteins. As lipoproteins play an important role in coronary artery disease development, their values have been the subject of intensive investigations over the last five decades. Plasma lipid concentrations are highly heritable and it is estimated that even 60-70 % of total plasma lipid values are attributable to these genetic factors. Before GWAS, our knowledge of those variants with strong effects on plasma lipids was limited and the reproducibility of results was low. But even during the pre-GWA era, recognition was given to the importance of variants within apolipoprotein E (as predictors of plasma total-and LDL-cholesterol values) (Eichner et al. 2002) and apolipoprotein A5 (as determinants of plasma triglycerides) (Pennacchio et al. 2001 , Hubacek 2016 .
The first four GWAS on this topic, all involving thousands of individuals, were published almost simultaneously and delivered surprisingly uniform results (Kathiresan et al. 2008 , Sandhu et al. 2008 , Willer et al. 2008 , Chasman et al. 2008 . They identified several new genes or loci that contribute to plasma lipid concentrations and confirmed a number of previously reported associations (Table 2) . Another "batch" of studies followed very soon after, including more samples and descriptions of more variants, and typically documenting the more minute effects of plasma lipids (Kathiresan et al. 2009 , Aulchenko et al. 2009 , Teslovich et al. 2010 , Global Lipids Genetics Consortium 2013 . These results were mostly summarized by Christoffersen and Tybjaerg-Hansen (2015) and by Schwarzova et al. (2015) . Table 2 . Selected examples of genes/variants with strong effects on plasma lipid parameters based on results from four GWAS (Kathiresan et al. 2008 , Sandhu et al. 2008 , Willer et al. 2008 , Chasman et al. 2008 . Variants used for the confirmatory study are in bold.
Gene for Variant Influenced parameter
Loci with prior evidence from association studies
As expected and based on the knowledge of lipid transport and metabolism (van Wijk et al. 2009 ), variants with strong effects have been detected within the enzyme HMGCoA reductase (a key enzyme of cholesterol biosynthesis), apolipoprotein B (a major structural protein of LDL particles), apolipoprotein E (maintains the structural integrity of lipoproteins and acts as a ligand for lipoprotein receptors), apolipoprotein A5 (an activator of lipoprotein lipase, which additionally reduces hepatic production of VLDL-particles) and the LDL receptor (a key receptor that is important in LDL particle assembly) ( Table 2) . It is important to note that new variants within these genes have been commonly found to be of higher importance in comparison with those variants analyzed during the pre-GWAS era.
More importantly, however, unexpectedly high numbers of significant variants have been detected within new, as yet unknown genes/loci ( Table 2) . One of the strongest GWA signals associated with plasma lipids is localized within the cluster of CELSR2/PSRC1/SORT1 genes. Other studies have identified the gene for sortilin as being responsible for the regulation of plasma cholesterol levels. Sortilin has been recognized as an intracellular apoB receptor, which facilitates the intrahepatic formation and transport of apoB-containing lipoproteins (Kjolby et al. 2010) .
Despite the undoubted advancements made by GWAS, these results still need to be replicated in independent populations, especially if they are to be used in clinical praxis.
The substantial lack of replication studies (for GWAS-obtained results) having been performed or published has possibly led to some bias, which means that the real effects on different populations may be over-or under-estimated (Munafò 2009). The major issue is that the original studies mostly include West-European populations S104 Hubacek et al. Vol. 66 only. Detailed analysis of interethnic variability, or even the differences between nationalities or possible gene-gene and gene-environment interactions, is entirely absent from these studies. Although the different effects of SNPs on males and females have been detected (Hubacek et al. 2008a , Heo et al. 2014 , Kulminski et al. 2015 and notwithstanding that GWAS usually comprise both males and females, the potential sex-specific effects have often not been analyzed/presented.
Based on the results of the first GWAS, we selected variants within seven genes (for more details, see Table 2 ) in order to replicate these results in the CzechSlavonic population and to confirm the potential universality of the effects. In addition to the individual gene effects, we constructed a risk score as a potentially more powerful predictor of plasma lipid values in the general population.
Methods

Analyzed subjects
We examined one group of adults (1,191 males and 1,368 females, aged 25-64 years; mean age of 49.0±10.7 years) , Hubacek et al. 2015a . The individuals had participated in the post-MONICA study (Cifkova et al. 2010) 
Genotype analysis
DNA was isolated using the standard salting-out method from whole EDTA blood (Miller et al. 1988) . Individual variants within the seven genes (rs646776 -CELSR2/PSRC1/SORT1 gene cluster, rs16996148 -CILP2/PBX4 gene cluster, rs693 and rs515135 -APOB, rs4420638 -APOE/C1/C4 gene cluster, rs12654264 -HMGCoA reductase, rs11206510 -PCSK9 and rs6511720 -LDL receptor) were genotyped using the polymerase chain reaction (PCR) and restriction analysis (Hubacek et al. 2015b) . The PCR device DYAD (MJ Research, Waltham, MA) and chemicals from Fermentas, Burlington, Canada were used. For more detailed PCR conditions, oligonucleotides and restriction enzymes, see Vrablik et al. (2012) .
Analysis of plasma lipids
Lipoprotein parameters (total cholesterol, HDL cholesterol and triglycerides) in fasting plasma samples were assessed using auto-analyzers and conventional enzymatic methods with reagents from Boehringer Mannheim Diagnostics and Hoffmann-La Roche in a CDC Atlanta-accredited local laboratory. LDL-cholesterol levels were calculated using the Friedewald formula: LDL-C = TC -HDL-C -(TG/2.2) (Friedewald et al. 1972) in subjects with TG values below 4.5 mmol/l. Dyslipidemic treatment was defined as the self-reported use of lipid-lowering drugs and/or diet.
Statistical analysis
The Hardy-Weinberg test (http://www.tufts.edu/ ~mcourt01/Documents/Court%20lab%20-%20HW%20 calculator.xls) was applied to confirm the independent segregation of alleles. ANOVA was used for statistical analysis. In cases where there was less than 5 % carriers of one genotype, these individuals were pooled with heterozygotes and analyzed together.
For polygenic analysis, an unweighted gene score was constructed according to the number of genotypes associated with higher plasma levels of LDL-cholesterol. Based on the number of negative genotypes from five variants within SORT1, CILP2, APOE, APOB and LDL-R, subjects were divided into six groups (from 0 up to 5 negative genotypes). We pooled groups with 0 and 1 and with 4 and 5 negative genotypes, respectively, as the numbers of individuals within the groups "0" and "5" were relatively low. The scores were used to analyze LDL-cholesterol values.
Due to the high number of performed comparisons, a significance level of P<0.01 was considered significant.
Results
Basic characteristics
The basic characteristics of the examined individuals are summarized in Table 3 . The achieved call rate for the examined polymorphisms varied between 91.8 % and 99.9 %. The frequencies of individual genotypes were similar to the frequencies detected within West-European Caucasians (Kathiresan et al. 2008 , Sandhu et al. 2008 , Willer et al. 2008 , Chasman et al. 2008 and did not differ significantly between males and females (for more details, see Table 4 ). Single nucleotide polymorphisms For most of the analyzed SNPs, we detected a significant influence on plasma lipid values in both males (Table 5) and females (Table 6) .
We observed the strongest effects on plasma lipid values (P<0.005 for LDL-C values) in the cases of the rs646776 variant within the SORT1 gene, the rs6511720 variant in the LDL-R gene and the rs693 variant within the APOB gene. And although adjustments for dyslipidemic treatment and age reduced this significance, all associations remained significant.
In contrast, we did not confirm an association between variants within the PCSK9 and HMGCoAr genes and plasma lipid values (not shown in detail). 
Gene score
The gene score was calculated from five SNPs within the genes for CILP2 (rs16996148), sortilin (rs646776), the LDL-receptor (rs6511720), APOE (rs4420638) and APOB (rs693). Both in males (N=993 with all five SNPs genotyped and valid LDL-C value) and females (N=1,155 with all five SNPs genotyped and valid LDL-C value), we were able to detect subjects across the entire span of the gene score.
Among the group with the lowest score, subjects with a maximum of one risky genotype were included. They exhibited LDL-C values of 3.35±1.01 mmol/l (males) or 3.17±1.12 mmol/l (females) in contrast with the group of subjects with at least four negative genotypes, where LDL-C values of 3.77±1.01 mmol/l (males) and 3.75±1.08 mmol/l (females) were detected. There was a significant linear trend (Fig. 1) between these groups and the differences were highly significant for both males (P<0.0005) and females (P<0.00005). After adjustments for dyslipidemic treatment and age, P values remained unchanged.
Discussion
In a large group of Slavonic Caucasian adults, we geographically extended the validity of previous findings (Kathiresan et al. 2008 , Sandhu et al. 2008 , Willer et al. 2008 , Chasman et al. 2008 focused on the genetic determination of plasma lipid levels. We confirmed strong significant effects of the common SNPs within SORT1, CILP2/PBX4, APOE, the LDL receptor and APOB on total plasma, LDL-cholesterol and plasma TG levels (CILP2/PBX4 loci only). These results were confirmed for both males and females, and age adjustment did not change the results significantly. We did not have information on female menopausal status, but it has been reported that normal physiological menopausal alterations do not significantly influence plasma lipid homeostasis (Wang et al. 2011) . Further, performed age adjustment could partially replace the adjustment for menopausal status and in our study, no major differences have been observed after the age adjustment. In contrast, we did not observe an association between the PCSK9 and HMGCoA reductase variants and plasma lipids in Czechs. In the case of the rs11206510 variant within the PCSK9 gene, the differences for LDL cholesterol were nominally high (about a 0.25 mmo/l difference for LDL-cholesterol), but the relatively low number of individuals with the protective CC genotype (~3 %) may explain why the differences did not reach significance.
For the polymorphism within the HMGCoA reductase gene, this approach could not explain the negative results (all LDL-cholesterol differences between homozygotes were below 0.09 mmol/l) and no association was detected even when all three possible models of the analysis (dominant, co-dominant and recessive) were used. The relatively low number of subjects included (in comparison with GWAS) may have led to this unexpected difference, but we cannot exclude also the possibility, that this SNP has no biologically significant effect on plasma lipids in Czechs. GWA screenings of plasma lipids have undoubtedly contributed to recent huge advancements in our knowledge in this field. However, despite the increasing popularity, the genome-wide association studies (Rosenberg et al. 2010 ) also have some pitfalls and limitations. Despite the extremely high P values obtained, these results still need to be replicated in order to negate the "winner's curse" effect. Further, it is well known that there are significant differences between populations and ethnic groups in the allelic frequencies of detected SNPs, in addition to environmental factors. These facts must surely impact on the global validity of the results obtained through such GWAS.
The results we have produced over recent years clearly show that GWAS results do not have absolute validity. We have focused on the replications of different GWAS findings in Czech-Slavonic population and, as expected, replicated some (Hubacek et al. 2008b (Hubacek et al. , 2012 but not all of the associations , Hubacek et al. 2013 , 2015c .
Our results point to a further important issue. In line with confirmation of the associations between single SNPs and some biochemical/anthropometrical markers, a much higher predictive value can be obtained when a polygenic score is created. Even though we used a simple and less precise unweighted score, the differences reached 12 % in males and 18 % in females between the extreme groups in the case of LDL-cholesterol.
Much recent discussion has focused on the issue of whether gene analysis can provide any extra benefit to the "traditionally" calculated risk score. Indeed, the conclusions drawn often dispute its value (Talmud et al. 2010 , Weijmans et al. 2015 , Morris et al. 2016 . However, these studies neglect to construct an overall view of the potential for the genetic prediction of disease. Using a gene profile to improve the risk calculation of cardiovascular disease in a 65-year-old man who is a lifelong smoker, obese and insulin-resistant is unlikely to be useful.
But it is of more benefit to determine genetic information for the timely estimation of disease risk in (very) young subjects (maybe even in children) to apply personalized and potentially long-term focused environmental intervention in order to postpone or even prevent the outbreak of disease.
Conclusions
We confirmed strong significant effects of common SNPs within the SORT1, CILP2/PBX4, APOE, LDL receptor and APOB (but not PCSK9 and HMGCoA-R) genes on plasma LDL-cholesterol levels and plasma TG levels (CILP2/PBX4 loci only) in both males and females. The unweighted gene score was linearly associated with plasma LDL-cholesterol and the effect of this score was much higher in comparison with individually analyzed polymorphisms.
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